MASSDEVICE ON CALL — Six-month data from the Levant-2 trial of C.R. Bard‘s (NYSE:BCR) Lutonix drug-coated balloon for treating femoropopliteal artery disease came as a surprise for those hoping the device will be a breakthrough treatment for peripheral artery disease.